Slight body weight and systolic blood pressure reduction are important beneficial effects. Main adverse events of SGLT2 inhibitors are genital mycotic and urinary tract infections. Dapagliflozin ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

This study by Hanlon and colleagues identified primarily age-related heterogeneity in the effects of SGLT2 inhibitors and GLP-1s on glycemic control and major adverse cardiovascular events ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

SGLT2 inhibitors and GLP-1 agonists also reduced the risk of major adverse cardiovascular events ... despite the glucose lowering effects being less in older people,” he noted.

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

Starting SGLT2 inhibitors led to a lower risk of eGFR ... an elevated risk of type 2 diabetes and accelerated progression to adverse vascular complications including CKD compared to their European ...

SGLT2 inhibitors and GLP-1 agonists also reduced the risk of major adverse cardiovascular events ... despite the glucose lowering effects being less in older people,” he noted. SGLT2 inhibitors were ...